Search Results - "Vlachostergios, P J"

Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients by Vlachostergios, P J, Gioulbasanis, I, Kamposioras, K, Georgoulias, P, Baracos, V E, Ghosh, S, Maragouli, E, Georgoulias, V, Papandreou, C N

“…Cancer patients frequently suffer from weight loss and systemic inflammation in the context of advanced disease, which is related to adverse outcome…”
Get more information

PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far? by Vlachostergios, P.J., Molina, A.M.

Get full text

Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors by Vlachostergios, P.J.

“…Numerous biomarkers are being tested to enhance the ability of clinicians to predict responses and prognosis after treatment with immune checkpoint inhibitors…”
Get full text

GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment by Vlachostergios, P. J., Balmiki, R. L., Daya, R.

Get full text

Bevacizumab in advanced cervical cancer by Vlachostergios, P. J., Papandreou, C. N.

Get full text

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer by Vlachostergios, P. J., Gioulbasanis, I., Ghosh, S., Tsatsanis, C., Papatsibas, G., Xyrafas, A., Hatzidaki, E., Vasiliou, C., Kamposioras, K., Agelaki, S., Margioris, A. N., Nasi, D., Georgoulias, V., Papandreou, C. N.

“…Objective Cancer patients usually develop malnutrition which may alter their innate immune system integrity. The aim of this study was to investigate the…”
Get full text

849PDPreliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) by Tagawa, S T, Osborne, J R, Hackett, A, Niaz, M J, Cooley, V, Christos, P, Vlachostergios, P J, Thomas, C, Gracey, L, Beltran, H, Molina, A M, Nanus, D M, Babich, J, Vallabhajosula, S, Sartor, O, Ballman, K, Bander, N H

“…Abstract Background PSMA is overexpressed in PC with limited expression in other organs. PC is radiosensitive with dose-response. Dose-fractionation allows…”
Get full text

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors by Antonarakis, E S, Velho, P Isaacsson, Agarwal, N, Santos, V Sacristan, Maughan, B L, Pili, R, Adra, N, Sternberg, C N, Vlachostergios, P J, Tagawa, S T, Bryce, A H, McNatty, A L, Reichert, Z R, Dreicer, R, Sartor, O, Lotan, T L, Hussain, M

“…Abstract Background Although once considered a homologous recombination DNA repair gene, CDK12 is now thought to have a distinct role in maintaining genomic…”
Get full text

Erratum to: Bortezomib represses HIF-1[alpha] protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells by Befani, C D, Vlachostergios, P J, Hatzidaki, E, Patrikidou, A, Bonanou, S, Simos, G, Papandreou, C N, Liakos, P

“…Issue Title: Understanding neuronal dysfunction and loss in neurodegenerative disease…”
Get full text

Erratum to: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells by Befani, C. D., Vlachostergios, P. J., Hatzidaki, E., Patrikidou, A., Bonanou, S., Simos, G., Papandreou, C. N., Liakos, P.

Get full text

Pulmonary and cutaneous nodules in an immunocompromised patient by Vlachostergios, Panagiotis J, Karamagkiolis, Spiros, Karamitsos, Konstantinos

Get more information

Common deleterious germline variants shape the urothelial cancer genome by Vosoughi, A, Zhang, T, Shohdy, KS, Vlachostergios, PJ, Wilkes, DC, Tagawa, ST, Nanus, SM, Molina, AM, Beltran, H, Sternberg, CN, Motanagh, S, Robinson, BD, Xiang, J, Chung, WK, Rubin, MA, Elemento, O, Sboner, A, Mosquera, JM, Faltas, BM

“…The prevalence and biological consequences of deleterious germline variants (DGVs) in urothelial cancer (UC) are unknown. We performed whole-exome sequencing…”
Get full text

Health-Related Quality of Life Assessment in Daily Urologic Practice: A Survey of Greek Urologists by Mitsogiannis, Iraklis C, Mitsogianni, Maria, Bakalis, Vissarion, Tzortzi de Paz, Anna, Vlachostergios, Panagiotis J, Tzortzis, Vassilios

“…Health-related quality of life (HRQoL) assessment has become an integral part of clinical research across different disciplines. However, the degree of…”
Get full text